Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials

BACKGROUND: Five severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are approved in North America and/or Europe: Pfizer/BioNTech, Moderna, Janssen, Oxford-AstraZeneca, and Novavax. Other vaccines have been developed, including Sinopharm, SinoVac, QazVac, Covaxin, Soberana, Zifivax...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez Navarro, Andrea, Pilkington, Victoria, Pepperrell, Toby, Mirchandani, Manya, Levi, Jacob, Hill, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Invited Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452066/
https://www.ncbi.nlm.nih.gov/pubmed/36092832
http://dx.doi.org/10.1093/ofid/ofac408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452066/
https://www.ncbi.nlm.nih.gov/pubmed/36092832
http://dx.doi.org/10.1093/ofid/ofac408

Ejemplares similares